Turkish Journal of Hematology (May 2016)

Comparison of Myelodysplastic Syndrome Prognostic Scoring Systems

  • Özlen Bektaş,
  • Ayşegül Üner,
  • Eylem Eliaçık,
  • Burak Uz,
  • Ayşe Işık,
  • Sezgin Etgül,
  • Süreyya Bozkurt,
  • İbrahim Celalettin Haznedaroğlu,
  • Hakan Göker,
  • Nilgün Sayınalp,
  • Salih Aksu,
  • Haluk Demiroğlu,
  • Osman İlhami Özcebe,
  • Yahya Büyükaşık

DOI
https://doi.org/10.4274/tjh.2014.0455
Journal volume & issue
Vol. 33, no. 2
pp. 119 – 126

Abstract

Read online

INTRODUCTION: Myelodysplastic syndrome (MDS) is a clonal hematopoietic stem cell disease. Patients are at risk of developing cytopenias or progression to acute myeloid leukemia. Different classifications and prognostic scoring systems have been developed. The aim of this study was to compare the different prognostic scoring systems. METHODS: One hundred and one patients who were diagnosed with primary MDS in 2003-2011 in a tertiary care university hospital's hematology department were included in the study. RESULTS: As the International Prognostic Scoring System (IPSS), World Health Organization Classification-Based Prognostic Scoring System (WPSS), MD Anderson Prognostic Scoring System (MPSS), and revised IPSS (IPSS-R) risk categories increased, leukemia-free survival and overall survival decreased (p<0.001). When the IPSS, WPSS, MPSS, and IPSS-R prognostic systems were compared by Cox regression analysis, the WPSS was the best in predicting leukemia-free survival (p<0.001), and the WPSS (p<0.001) and IPSS-R (p=0.037) were better in predicting overall survival. DISCUSSION AND CONCLUSION: All 4 prognostic systems were successful in predicting overall survival and leukemia-free survival (p<0.001). The WPSS was found to be the best predictor for leukemia-free survival, while the WPSS and IPSS-R were found to be the best predictors for overall survival.

Keywords